Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biogen Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

68 comunicati stampa

Guarda tutti i comunicati
17/06/2026
Biotecnologia
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Biotecnologia
Annunci Economici
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
03/06/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
14/05/2026
Biotecnologia
Medicina Salute Benessere
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnologia
Management/Organizzazione Aziendale
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
31/03/2026
Biotecnologia
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
30/03/2026
Biotecnologia
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotecnologia
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
19/03/2026
Biotecnologia
Medicina Salute Benessere
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
11/03/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0